Literature DB >> 11229454

The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis.

L C Hofbauer1, A E Heufelder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11229454     DOI： 10.1002/1529-0131(200102)44:2<253::AID-ANR41>3.0.CO;2-S

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  26 in total

Review 1.  Role of nuclear factor kappaB in synovial inflammation.

Authors:  Ulf Müller-Ladner; Renate E Gay; Steffen Gay
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

2.  Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis.

Authors:  Nathalie Saidenberg-Kermanac'h; Natacha Bessis; Delphine Lemeiter; Marie-Christine de Vernejoul; Marie-Christophe Boissier; Martine Cohen-Solal
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

3.  Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy.

Authors:  Tetsuya Amano; Satoshi Yamasaki; Naoko Yagishita; Kaneyuki Tsuchimochi; Hiroshi Shin; Ko-ichi Kawahara; Satoko Aratani; Hidetoshi Fujita; Lei Zhang; Rie Ikeda; Ryoji Fujii; Naoki Miura; Setsuro Komiya; Kusuki Nishioka; Ikuro Maruyama; Akiyoshi Fukamizu; Toshihiro Nakajima
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

4.  Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.

Authors:  Shengqian Xu; Yu Wang; Jingqiu Lu; Jianhua Xu
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

5.  Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand.

Authors:  Alfons S K de Hooge; Fons A J van de Loo; Miranda B Bennink; Diana S de Jong; Onno J Arntz; Erik Lubberts; Carl D Richards; Wim B vandDen Berg
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

6.  Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.

Authors:  Yu Asanuma; Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein
Journal:  Atherosclerosis       Date:  2007-06-14       Impact factor: 5.162

7.  Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis.

Authors:  Shilpi Agarwal; Ramnath Misra; Amita Aggarwal
Journal:  Rheumatol Int       Date:  2008-12-04       Impact factor: 2.631

8.  Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.

Authors:  Kageyama Yasunori; Takahashi Masaaki; Nagafusa Tetsuyuki; Kobayashi Hayato; Nagano Akira
Journal:  Clin Rheumatol       Date:  2008-03-13       Impact factor: 2.980

Review 9.  Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis.

Authors:  Maria V Barbolina; M Sharon Stack
Journal:  Semin Cell Dev Biol       Date:  2007-07-10       Impact factor: 7.727

10.  Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy.

Authors:  Hubert Marotte; Pierre Miossec
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.